MedTech Innovation is accelerating in India as Tata Elxsi partners with Sree Chitra Tirunal Institute for Medical Sciences and Technology
The Top News from the pharmaceutical sector this week reflects a rapidly evolving landscape driven by innovation, regulation, and global health priorities
India is strengthening its healthcare ecosystem through new institutional collaborations to accelerate Medical Research in India, with a clear focus on improving patient-centric outcomes through data-backed and evidence-based practices
Cipla has reported its highest-ever quarterly sales record in India, marking a strong start to Q1 FY27. The company's domestic business grew 12 percent year-on-year and became the biggest growth driver. Cipla also delivered steady gains across globa
Dr. Singh shares how Indian pharmaceutical companies can navigate stricter global regulations, foster sustainable quality, embrace digital transformation, and strengthen their position in the global pharmaceutical market.
GSK has received Early FDA Approval for its new lung cancer drug, Jideytro. The decision marks a major milestone for the company as it enters the competitive market for targeted lung cancer therapies.
Trump’s new tariff plan has raised fresh concerns for Indian pharma companies that depend on the US market. US President Donald Trump announced a phased tariff policy for imported generic drugs.
International researchers have raised fresh concerns over papaya cancer research conducted by Tata Memorial Centre. They have questioned whether the study provides enough evidence to support its conclusions.
India has cleared Fasenra expansion as AstraZeneca targets severe asthma patients with a wider treatment option.
Merck’s cholesterol pill is poised to reshape the global cardiovascular drug landscape, this comes with the latest approval from the U.S. Food and Drug Administration for its first-in-class oral PCSK9 inhibitor
, CDSCO.jpg)